Your child may well be the only child -- in fact, she may be the only, or one of two or three, patients diagnosed or suspected of having SCLS -- in this virtual community who is receiving subcutaneous immunoglobulin, which is a rather new product on the market.
Hizentra delivers immunoglobulins at twice the usual concentration, namely 20% rather than the usual 10% featured in intravenous immunoglobulin (IVIG).
The advantage is that one can use a small needle and infusion pump and administer it subcutaneously and not into a vein, such that it can be injected at one's convenience by a trained adult at home or elsewhere.
The disadvantage, I gather, is that one's body may react much more severely to the concentrated product than the rest of us do to IVIG. According to the manufacturer, CSL Behring -- the same company that makes Privigen, which is what I get intravenously -- "in the U.S. clinical trial for Hizentra, the most common adverse reactions were redness, swelling, itching, heat, or pain at the infusion site, 93% of which were mild while 6% were moderate. Other common side effects observed were headache, vomiting, pain, and fatigue."
Talk it over with your doctors, but it seems to me that the practical choices you have are (1) to slow down the infusion rate; (2) to give her a half-dose of the medication every week instead of a full dose every other week; or (3) to switch back to IVIG on an every-other-week basis.
We have several adult patients who get IVIG this way -- a minority -- either because the side effects of a once-monthly regimen were deemed to be intolerable, or else because receiving half a dose every 2 weeks seems to prevent what may have been mild episodes of SCLS towards the end of the 4-week period.